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Obesity-induced insulin resistance is the major determinant of metabolic syndrome, which
precedes the development of type 2 diabetes mellitus and is thus the driving force behind the
emerging diabetes epidemic. The precise causes of insulin resistance are varied, and the relative
importance of each is a matter of ongoing research. Here, we offer a Perspective on the heteroge-
neous etiology of insulin resistance, focusing in particular on the role of inflammation, lipid metab-
olism, and the gastrointestinal microbiota.Introduction
Insulin resistance is the key etiologic defect that defines meta-
bolic syndrome (Moller and Kaufman, 2005). After initiation of
the insulin-resistant, metabolic syndrome state, many of these
patients eventually develop b cell failure, which triggers the onset
of type 2 diabetes mellitus (T2DM). The incidence of T2DM has
risen dramatically in the past couple of decades, now affecting
>300million people worldwide, including an estimated 55 million
in India, 25 million in the United States, and 80 million in China,
with great human and financial costs. In parallel, there has
been an even more dramatic epidemic of obesity, and because
obesity is the most common cause of insulin resistance in
man, it is the obesity epidemic that is driving the parallel T2DM
epidemic. Indeed, >80% of people with T2DM in the United
States are classed as overweight. Therefore, obesity-induced
insulin resistance is the dominant factor underlying both meta-
bolic syndrome and the rising tide of T2DM.
It is clear that T2DM is a heterogeneous disease, and the
etiology of insulin resistance is equally complex (Moller and
Kaufman, 2005). There are a number of known causes of insulin
resistance, as well as competing views as to their relative impor-
tance. Our view is that insulin resistance is a multifactorial condi-
tion in which overnutrition triggers increased inflammation (Gre-
gor and Hotamisligil, 2011), changes in lipid metabolism (Samuel
and Shulman, 2012), and changes in the gastrointestinal (GI) mi-
crobiota (dysbiosis) (Kau et al., 2011; Nicholson et al., 2012), all
of which are interconnected to varying degrees, leading to the
final state of insulin resistance. In this Perspective, we will not
highlight all areas implicated in insulin resistance, as we believe
that inflammation, lipid metabolism, and the microbiota are the
major interacting components and that other proposed factors
ultimately work through one or more of these mechanisms. Nor
will we attempt an exhaustive review of these three areas, as
excellent and more detailed reviews have recently been pub-
lished (Gregor and Hotamisligil, 2011; Kau et al., 2011; Lumeng
and Saltiel, 2011; Nicholson et al., 2012; Saltiel, 2012; Samuel
and Shulman, 2012). Instead, we will offer our view as to how
inflammation, lipids, and dysbiosis work together to causedecreased insulin sensitivity andwill discuss commonmisunder-
standings, gaps in our knowledge, and challenges in the field.
Finally, we will focus on current therapeutic strategies, as it is
quite clear that our basic research and preclinical knowledge
of these processes surpass our ability to use these insights for
a better understanding of human disease and its treatments.
Inflammation-Mediated Insulin Resistance
Chronic, low-grade tissue inflammation is a major and well-
known cause of obesity-induced insulin resistance (Gregor and
Hotamisligil, 2011; Lumeng and Saltiel, 2011). Initial landmark
observations in this area were made by Hotamisligil et al., who
showed an increase in tumor necrosis factor a (TNF-a) concen-
tration in obese adipose tissue and that TNF-a neutralization
improves insulin sensitivity in obese rodent models (Hotamisligil
et al., 1993, 1996). Later studies by Weisberg et al. and Xu et al.
demonstrated that adipose tissue from obese humans and mice
is characterized by a striking accumulation of macrophages.
Indeed, up to 40% of all cells in obese adipose tissue are infil-
trating macrophages (Weisberg et al., 2003; Xu et al., 2003).
Subsequent studies have demonstrated that adipose tissue
macrophages (ATMs) are highly activated, with increased
expression of a large array of proinflammatory genes (Lumeng
et al., 2007; Nguyen et al., 2007). These proinflammatory genes
include a set of cytokines, particularly TNF-a, that are exces-
sively secreted from activated macrophages and directly cause
insulin resistance by acting on insulin target cells in local tissues
through paracrine mechanisms (Hotamisligil et al., 1993, 1996).
For example, TNF-a signaling activates intracellular kinases,
such as c-Jun N-terminal kinase (JNK) and IkB kinase (IKK),
which inhibit insulin receptor signaling by serine phosphorylation
of insulin receptor substrate 1 (IRS-1). Furthermore, activation of
the transcription factors AP-1 and NF-kB results in a feed-
forward mechanism whereby proinflammatory cytokine produc-
tion is exacerbated. If the magnitude of cytokine secretion is
great enough, they can leak out of the tissue, raising circulating
levels, to produce endocrine effects on distant organ systems,
such as muscle and liver, exacerbating systemic insulinCell 152, February 14, 2013 ª2013 Elsevier Inc. 673
resistance (Osborn and Olefsky, 2012). However, the adipose
tissue concentrations of cytokines are much higher than circu-
lating levels, and it is likely that, in most circumstances, themajor
effects of these secretory products are local rather than systemic
(Hotamisligil et al., 1995).
Although increased adiposity causes insulin resistance, it has
long been known that visceral adipose tissue has amuch greater
negative metabolic effect than subcutaneous adipose tissue. In
obesity, increased macrophage accumulation and other signs
of inflammation occur in the visceral adipose tissue, but not in
the subcutaneous depots, consistent with the negative impact
of visceral adipose expansion on insulin sensitivity.
Liver and Hypothalamic Inflammation in Obesity
Similar etiologic events can also occur in the liver (Gregor and
Hotamisligil, 2011; Osborn and Olefsky, 2012). During obesity,
there is a substantial increase in hepatic macrophages (Obstfeld
et al., 2010). Liver macrophages consist of a resident macro-
phage population, termed Kupffer cells, and recruited hepatic
macrophages (RHMs), which migrate into the liver under obese
conditions (Obstfeld et al., 2010; Oh et al., 2012). Kupffer cells
are bonemarrow derived and form a stable long-lived population
of resident macrophages in the liver (Klein et al., 2007). However,
the exact cell type that gives rise to Kupffer cells remains
unknown. RHMs are also bone marrow derived, migrate to the
liver under the influence of liver-derived chemokines, particularly
MCP-1, and are highly proinflammatory in the context of obesity
(Obstfeld et al., 2010; Oh et al., 2012). Based on recent studies,
30%–70% of all hepatic macrophages in obesity are RHMs (Oh
et al., 2012). These cells turn over in amatter of weeks and do not
give rise to Kupffer cells. Chemically mediated depletion of
Kupffer cells and RHMs by gadolinium (Neyrinck et al., 2009)
or clodronate (Lanthier et al., 2010) treatment ameliorates
hepatic insulin resistance, and thus, in obesity, both RHMs cells
and Kupffer cells are responsible for the chronic hepatic inflam-
matory state. However, the relative contributions of these
different cell types to hepatic inflammation and insulin resistance
remain unresolved. It has also been shown that obesity is asso-
ciated with hypothalamic inflammation and that the resulting
local production of proinflammatory cytokines can cause central
leptin resistance, a key feature of obesity. In addition, central
nervous system (CNS) inflammation can contribute to systemic
insulin resistance, particularly in the liver, via a brain-liver
neuronal signal (Milanski et al., 2012). Thus, inflammation in the
CNS during obesity may be a key determinant of weight gain
and systemic insulin sensitivity.
Macrophages and Insulin Resistance
The diversity of ATMs, Kupffer cells, and RHMs indicates that
tissue macrophages consist of heterogeneous populations
with differential functions (Mosser and Edwards, 2008). Based
on in vitro studies, macrophages can be divided into M1 and
M2 classifications (Gordon and Martinez, 2010). M1 macro-
phages, also termed ‘‘classically activated macrophages,’’ are
highly proinflammatory, secreting the bulk of the cytokines that
cause insulin resistance. M2 macrophages, also termed ‘‘alter-
natively activated macrophages,’’ are not inflammatory and
give rise to cytokines that exert anti-inflammatory effects, such
as IL-10 and IL-4 (Gordon and Martinez, 2010). However, in the
in vivo situation, macrophages do not conveniently fall into either674 Cell 152, February 14, 2013 ª2013 Elsevier Inc.exclusively M1 or M2 phenotypes and exist across a polarization
spectrum from the most inflammatory to noninflammatory cells
(Jenkins et al., 2011; Mosser and Edwards, 2008). The overall
macrophage-induced inflammatory state of the tissue is deter-
mined by the balance between these different macrophage
subpopulations. In the obese state, the balance is clearly tilted
toward the proinflammatory macrophage phenotype (Gregor
and Hotamisligil, 2011).
The role of these inflammatory macrophages in causing
decreased insulin sensitivity has been repeatedly demonstrated.
Most compelling are a large number of studies in which macro-
phage inflammatory pathways have been genetically manipu-
lated through loss- or gain-of-function approaches to show
that decreased or increased macrophage-mediated inflamma-
tion leads to insulin sensitization or insulin resistance, respec-
tively (see Osborn and Olefsky [2012] for references). In addition,
complementary findings have been generated in man, although
in comparison to the studies in rodents, the body of work is by
necessity largely descriptive and correlative. As examples, inter-
ventions that improve insulin sensitivity, such as weight loss
(Forsythe et al., 2008) and exercise (Teixeira-Lemos et al.,
2011), decrease inflammation, whereas manipulations that
cause insulin resistance, such as lipid overload, increase inflam-
mation (Tripathy et al., 2003). Again, however, these are correla-
tive studies, and clear data from pharmacologic anti-inflamma-
tory therapy for the treatment of insulin resistance has
remained an elusive goal.
Nonmacrophage Immune Cells and Insulin Resistance
Macrophages are by no means the only immune cell type that
participates in the process of inflammation-induced insulin resis-
tance. Neutrophils (Talukdar et al., 2012) and mast cells (Liu
et al., 2009) are increased in obese adipose tissue, and studies
in mice have indicated that these two cell types can promote
insulin resistance. Lymphocytes also play an important role. B
lymphocytes (Winer et al., 2011), CD8+ cytotoxic T lymphocytes
(Nishimura et al., 2009), and CD4+ Th1 cells (Winer et al., 2009)
promote insulin resistance, whereas CD4+ regulatory T (Treg)
cells are anti-inflammatory (Cipolletta et al., 2012; Feuerer
et al., 2009). Lymphocytes require the presentation of antigen
and costimulation by macrophages/dendritic cells for their acti-
vation, and therefore, these immune cell populations are inter-
reliant. The numbers of Tregs and Th2 cells are absolutely or
relatively decreased in obese adipose tissue (Feuerer et al.,
2009; Winer et al., 2009), and these cells serve an important
function in modulating macrophage behavior. Treg and Th2 cells
can inhibit polarization of proinflammatory macrophages and
can also prevent their recruitment into tissues. Adipose tissue
Treg cell numbers can be restored in mice fed a high-fat diet
(HFD) by insulin-sensitizing Thiazolidinedione (TZD) therapy,
and this likely forms part of the mechanism of action for these
drugs (Cipolletta et al., 2012). Another checkpoint promoting
the anti-inflammatory state is providedbyeosinophils, andadefi-
ciency of adipose tissue eosinophils has been reported to cause
insulin resistance (Wu et al., 2011a). Lastly, deficiency of natural
killer T (NKT) cells, which can respond to lipid antigen, reduces
glucose tolerance in 18-week-old lean mice (Schipper et al.,
2012), although a separate study found no effect in younger
mice (Kotas et al., 2011). Absence of NKT cells has no effect
Figure 1. The Immune Response in Obese Adipose Tissue
Release of chemokines, such as MCP-1 and LTB4, facilitates the recruitment
of inflammatory adipose tissue macrophages (ATMs) from blood monocytes.
ATMs can sense ‘‘danger’’ signals, such as free fatty acids (FFAs) and lipo-
polysaccharide (LPS), and produce inflammatory cytokines, such as TNF-a.
ATMs can also engage effector lymphocyte populations, CD4+ Th1 cells, andon glucose tolerance in obese mice (Ji et al., 2012; Kotas et al.,
2011; Mantell et al., 2011; Schipper et al., 2012).
It is of interest, and somewhat puzzling, that individual studies
exist, supporting an important role for each of these cell types in
the etiology of inflammation-mediated insulin resistance. In the
in vivo situation, it is unlikely that these cell typeswork in isolation
but, rather, are part of an ongoing interactive immune cell
conversation (see Figure 1). It is possible that time-course
studies could reveal insights into the primary and secondary
events in adipose tissue immune cell interactions. Although
detailed time-course data assessing each of the aforementioned
immune cell types have not been published within a single study,
it has been shown that neutrophils and M1-like macrophages
accumulate in adipose tissue as early as 3–14 days after HFD
feeding, plateauing at maximal accumulation several weeks later
(Lee et al., 2011; Strissel et al., 2010; Talukdar et al., 2012; Winer
et al., 2011) and that Th1 cells, Th2 cells, and B lymphocytes
begin to accumulate at 4 weeks according to Winer et al.
[2011] or at 22 weeks according to Strissel et al. [2010].
This immune cell cooperation would mean that inhibition of
any component within this interlinked cellular network can
disrupt the overall inflammatory state. Because macrophages
are the most abundant proinflammatory immune cell type in
adipose tissue and liver, it is likely that they represent the final
effector cell secreting the predominance of the cytokines that
cause insulin resistance. However, in vivo, it is most likely that
several immune cell types work together in a more integrated
fashion to achieve the common goal, meaning that, from a treat-
ment point of view, there are many potential entry points for ther-
apeutic intervention.
Lipids and Insulin Resistance
A variety of abnormalities in lipid metabolism have been
described in insulin-resistant states, some of which may be the
result of insulin resistance, whereas others may participate in
causality. The concept of lipotoxicity holds that increased levels
of circulating fatty acids and/or lipid accumulation in muscle and
liver can lead to insulin resistance (Samuel and Shulman, 2012).
In this way, lipotoxicity is a contributing factor to the pathophys-
iology of the metabolic derangements in obesity and T2DM, and
in general, there are two overall ways in which lipids can nega-
tively impinge on insulin action. First, circulating fatty acids can
activate cell-signaling pathways, which interfere with insulin
action (Glass and Olefsky, 2012). Second, metabolism of fats
can lead to the accumulation of intracellular lipid products, which
cause insulin resistance (Jornayvaz and Shulman, 2012) (see
Figure 2). In T2DM, hyperglycemia can also have a detrimental
impact on insulin signaling (glucotoxicity), and in the diabetic
state, the negative effects of lipotoxicity and glucotoxicity might
be additive.
Fatty Acid Signaling and Insulin Resistance
Circulating fatty acid levels are often elevated in obese and/or
diabetic states, and saturated fatty acids (SFAs) can activate
cellular proinflammatory pathways through Toll-like receptor 4CD8+ cytotoxic T lymphocytes (CTLs), which act to enhance ATM recruitment
and supplement effector cytokine production. ATM recruitment and inflam-
matory function can be inhibited by resident Treg cells.
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Figure 2. Pathways Leading to Lipid-
Mediated Insulin Resistance
Fetuin-A (FetA)-bound saturated fatty acids (SFAs)
can signal via TLR4 to induce proinflammatory
responses and inhibitory IRS phosphorylation.
Alternatively, SFAs can be metabolized to ce-
ramides or diacylglycerol (DAG), which reduce
insulin sensitivity via AKT inhibition or inhibitory
IRS phosphorylation. TLR4 signaling can syner-
gize with the ceramide pathway by promoting
transcription of ceramide biosynthetic genes as
well as cytokines. Conversely, some FFAs can
also be anti-inflammatory. For example, u-3 FAs
signal via GPR120 and inhibit TLR4 signaling via
sequestration of Tak1.(TLR4)-dependent mechanisms, demonstrating the link between
this form of lipotoxicity and inflammatory signaling (Lee et al.,
2001; Shi et al., 2006). Stimulation of TLR4 by SFAs induces acti-
vation of JNK and IKK, which directly inhibit insulin signaling via
serine phosphorylation of IRS-1 (Glass and Olefsky, 2012).
Furthermore, activation of these kinases leads to NF-kB and
AP-1 activation and changes in the expression of genes that influ-
ence insulin action, providing an additional mechanism for SFA-
induced insulin resistance (Glass and Olefsky, 2012). Activation
of the inflammasome can also be a consequence of SFA stimula-
tion (Wen et al., 2012). The inflammasomemediates the caspase-
1-driven cleavage of pro-IL-1b and pro-IL-18, leading to the
secretion of the active forms of these cytokines; deficiency of in-
flammasome components (such as Nlrp3) ameliorates insulin
resistance. Thus, SFA-induced inflammasome activation exac-
erbates inflammation, resulting in the inhibition of insulin action.
Although TLR4 is an important component of SFA-induced
insulin resistance (Lee et al., 2001; Nguyen et al., 2007; Shi
et al., 2006), recent work indicates that SFAs are not direct
ligands for TLR4, raising the question of how they work. This
question has recently been addressed by the studies of Pal
et al. (2012), who demonstrated that Fetuin A, a circulating glyco-
protein secreted from the liver, binds SFAswith high affinity, and,
in turn, Fetuin A binds to and activates TLR4. In this way, Fetuin A
provides the physical link between SFAs and TLR4 signaling.
SFAs can also be incorporated into specific lipid raft domains
of the plasma membrane, where they enhance TLR4 dimeriza-
tion and c-Src recruitment (Holzer et al., 2011; Wong et al.,
2009). This activates downstream stress signaling pathways
(such as JNK/AP-1) that inhibit insulin action (Wong et al., 2009).
Certain classes of lipids can also exert anti-inflammatory
effects. For example, fish oils or omega-3 fatty acids DHA and
EPA exert potent anti-inflammatory effects (Serhan et al.,
2008). Recently, it has been found that GPR120 onmacrophages
and adipocytes functions as the receptor or sensor for omega-3676 Cell 152, February 14, 2013 ª2013 Elsevier Inc.fatty acids, activating a b-arrestin2/TAB1
signaling system that blocks intracellular
proinflammatory pathways, preserving
insulin sensitivity (Ichimura et al., 2012;
Oh et al., 2010). Interestingly, the recent
identification of a loss-of-function poly-
morphism in the human Gpr120 gene
associated with obesity suggests a rolefor this anti-inflammatory lipid pathway in man (Ichimura et al.,
2012).
Tissue Lipid Metabolism and Insulin Resistance
Excessive accumulation of intracellular lipid products is another
proposed mechanism for insulin resistance (Samuel and Shul-
man, 2012). A general concept related to this mechanism is
that fat calories ingested in excess of caloric needs are stored
in adipose tissue. This has led to the proposal that, in obesity,
the excessive fat calorie load is so high that it exceeds the buff-
ering capacity and efficiency of adipose tissue storage so that
these excess fat calories ‘‘spill over’’ into other tissues like skel-
etal muscle and liver (Danforth, 2000; Shulman, 2000). Indeed,
increased skeletal muscle triglyceride concentrations and
hepatic steatosis are typical concomitant abnormalities of
insulin resistance states (Samuel and Shulman, 2012).
However, even though this ‘‘spillover’’ concept is straightfor-
ward, it is also an oversimplification and is unlikely to be correct
in the typical sense of its use. As a case in point, if a given indi-
vidual gains 50 pounds to become obese, it is very likely that he
or she will have some degree of steatosis and increased intra-
muscular triglyceride (IMTG) levels. This ‘‘spillover’’ cannot be
due to the fact that the adipose tissue compartment is satu-
rated, as such individuals can easily gain 20, 50, or even 100
additional pounds. Furthermore, the amount of lipid accumula-
tion in muscle and liver in obesity amounts to no more than
a couple of pounds. Thus, the build-up of hepatic and muscle
lipids must result from a more complex mechanism. One
component could be a simple kinetic issue of lipid flux in which
liver and muscle normally clear a certain percentage of the
incoming fat load; in obesity, this fraction could be slightly
increased and, over time, lead to the observed lipid accumula-
tion. Another possibility is that, when liver and muscle become
insulin resistant, lipid metabolism is reprogrammed with
a proportional increase in fatty acid re-esterification or de
novo lipogenesis. Most likely both and perhaps additional
mechanisms exist to account for tissue lipid accumulation
outside of the adipose depots.
This raises the key question as towhether lipid accumulation in
liver and muscle is the result or the cause of insulin resistance.
Here there are strong proponents of both views. For example,
there are a number of situations in which steatosis and increased
IMTGs exist in the absence of decreased insulin sensitivity,
arguing against a causal role for lipid accumulation in insulin
resistance (Cohen et al., 2011). On the other hand, metabolism
of excessive fatty acid loads can result in the generation of
bioactive lipid products that can attenuate insulin signaling (Jor-
nayvaz and Shulman, 2012). As is the case in most complex, in-
terconnected metabolic abnormalities, both sides are probably
partially correct. Clearly, tissue lipid accumulation can serve as
a biomarker for the insulin-resistant state, as increased hepatic
and IMTG content is a typical concomitant of insulin resistance,
particularly in obesity. Good evidence for the lipotoxicity
concept also exists, as both diacylglycerides (DAGs) and ceram-
ides can lead to decreased insulin signaling. Thus, fatty-acid-
derived DAGs stimulate protein kinase C (PKC) activity, which
leads to inhibitory serine phosphorylation of insulin signaling
components (such as IRS proteins), causing insulin resistance
(Samuel and Shulman, 2012). Similarly, SFAs can be converted
to ceramides that inhibit AKT activity and decrease insulin sensi-
tivity (Stratford et al., 2004). Inflammatory pathway activation can
also connect excessive tissue lipids and insulin resistance. Acti-
vation of inflammatory pathways stimulates the expression of
a set of genes involved in ceramide biosynthesis (Holland
et al., 2011). In this way, inflammatory signaling potentiates ce-
ramide production, emphasizing the interplay between inflam-
mation and lipid-mediated insulin resistance and providing an
additional mechanism for inflammation-induced decreased
insulin sensitivity. Excessive fatty acid influx can also overwhelm
the mitochondrial capacity for b oxidation, resulting in a build-up
of partially oxidized acylcarnitine intermediates, which might
contribute to insulin resistance (Muoio and Neufer, 2012). This
subject has been extensively reviewed (Samuel and Shulman,
2012), and despite many publications on the subject, a definitive,
consensus view has yet to emerge. The two points of view are
not mutually exclusive, and it is certainly possible that tissue lipid
accumulation is both a biological marker that results from insulin
resistance and a contributing factor under certain circum-
stances.
Models of Fat-induced Insulin Resistance
Feeding rodents high-fat diets (HFDs) causes weight gain with
expansion of adipose tissue mass, and HFD-fed mice and rats
are typically used as a model to study the detailed pathophysio-
logic consequences of obesity. In fact, HFD-fed mice are
frequently referred to as diet-induced obese (DIO) animals.
Alhough this is correct, normal chow diets typically contain
4%–6% fat, whereas HFDs are commonly 45%–60% fat, and
so DIO rodents are also models of high fat intake. Thus, interpre-
tation of such studies must always be mindful of the possibility
that the excessive fat intake or composition, rather than the
underlying obesity, may be responsible for some of the specific
phenotypic features in this model. This is not the case with ob/ob
or gold thioglucosemice, which become obese due to increased
caloric intake of normal chow diets.Another way to assess themetabolic effects of lipid overload is
to acutely infuse lipid emulsions to abruptly raise circulating free
fatty acid (FFA) levels, and this maneuver will cause decreased
insulin sensitivity within a couple of hours (Boden et al., 2002).
Acute lipid infusions and chronic HFD are often viewed as inter-
changeable models to create lipid overload for studies of meta-
bolic sequelae. However, the mechanisms whereby acute eleva-
tions of FFAs and chronic HFD cause decreased insulin
sensitivity may not be the same, and evidence has already
been published to this effect (Lee et al., 2011). For example, lipid
infusions present a large acute lipid load to tissues with abrupt
lipotoxic effects. Chronic HFD leads to long-term, gradual lipid
storage and obesity, and this model results in chronic tissue
inflammation, changes in the GI microbiota (dysbiosis), and hy-
perinsulinemia, which are not features of acute lipid infusion.
Therefore, one should not conflate these approaches from
a mechanistic point of view because it is likely that they produce
the end result of insulin resistance through somewhat different
pathways.
Gut Microbial Influence on Obesity and Insulin
Resistance
The microbiota of the gastrointestinal (GI) tract has a profound
impact on host physiology (Blumberg and Powrie, 2012; Kau
et al., 2011; Nicholson et al., 2012). The collective microbiota
genome, termed the microbiome, can also be studied, and there
is great interest in the contributions of the microbiota to energy
metabolism and metabolic disease.
In mousemodels of obesity, the composition of themicrobiota
is altered—a phenomenon referred to as dysbiosis (Hildebrandt
et al., 2009; Ley et al., 2005; Turnbaugh et al., 2008). Specifically,
a decrease in Bacteroidetes species and an increase in Firmi-
cutes species are associated with the obese state. Gnotobiotic
(germ-free) mice are resistant to obesity induced by a HFD
(Ba¨ckhed et al., 2007), and colonization of gnotobiotic mice
with a conventional mouse microbiota increases adipose tissue
mass (Ba¨ckhed et al., 2004). This increased adiposity is exagger-
ated when gnotobiotic mice are colonized with the microbiota
derived from obese animals, indicating that the composition of
the microbiota can predispose to the development of obesity
(Turnbaugh et al., 2006). In addition, increased levels of circu-
lating bacteria or bacterial products, such as lipopolysaccharide
(LPS), which are derived from the microbiota, have been associ-
ated with insulin resistance (Burcelin et al., 2012).
Cause versus Consequence
Whether microbial dysbiosis is a cause or consequence of
obesity and/or insulin resistance is a matter of ongoing debate
(Blumberg and Powrie, 2012), given that most studies describe
associations of dysbiosis with metabolic disease rather than
mechanistic connections (Ley et al., 2005; Serino et al., 2012).
It is also possible that reverse mechanisms exist in which
some aspect of obesity itself can cause dysbiosis. Intervention
studies will be necessary to sort out these ‘‘cause versus effect’’
questions, and indeed some positive steps have been made in
this regard. Transfer of a dysbiotic microbiota into a lean mouse
recipient will induce increased adiposity or weight gain (Henao-
Mejia et al., 2012; Turnbaugh et al., 2006). Additionally, in mouse
studies, antibiotic, prebiotic, and probiotic intervention canCell 152, February 14, 2013 ª2013 Elsevier Inc. 677
Figure 3. Microbial Contribution to Insulin
Resistance
The intestinal immune response, such as IgA
antibodies and antimicrobial peptides (AMPs),
influence and are influenced by the gastrointes-
tinal microbiota. Under homeostatic conditions,
the intestinal immune system helps to preserve
systemic ignorance of intestinal bacteria and also
regulates its composition over time. A dysbiotic
microbiota contributes to insulin resistance by
increased energy harvest and the direct effect of
altered bacterial metabolite production (e.g.,
short-chain fatty acids [SCFAs] and bile acid
derivatives) on the liver and adipose tissue. In
addition, gastrointestinal permeability caused by
either intestinal inflammation or intestinal immune
dysfunction results in penetration of bacteria or
bacterial products (e.g., LPS, DNA), which can
drive systemic inflammation.improve insulin sensitivity (Amar et al., 2011a; Cani et al., 2008;
Membrez et al., 2008).
Potential Mechanisms and Outstanding Questions
The microbiota influences energy harvest, energy metabolism,
and the development of systemic inflammation (Nicholson
et al., 2012). Bacteria can complement digestive function, such
as fermentation of complex carbohydrates to short-chain fatty
acids (SCFAs), a function predominantly assigned to Firmicutes.
Indeed, energy stores are elevated following colonization of
gnotobiotic mice with a conventional microbiota demonstrated
by increases in adiposity and hepatic triglycerides (Ba¨ckhed
et al., 2004), and the obesity-associated microbiota has an
enhanced capacity to harvest energy from the diet (Turnbaugh
et al., 2006). Several studies have proposed that chronic low-
grade intestinal inflammation in HFD-fed mice can cause intes-
tinal permeability or ‘‘leakiness’’ (de La Serre et al., 2010; Ding
et al., 2010; Li et al., 2008), and genetic ablation of certain host
immune defense components (e.g., MyD88/Trif/ or Asc/)
can result in intestinal bacteria or bacterial products penetrating
systemically (Henao-Mejia et al., 2012; Slack et al., 2009). There-
fore, intestinal inflammation or intestinal immune dysfunction
may cause GI permeability, leading to increased circulating
LPS and bacterial DNA, which are key factors promoting
systemic inflammation and insulin resistance in both mice and
humans (Burcelin et al., 2012) (Figure 3).
Through their activity in the lumen, the microbiota also
produce bioactive metabolites, including SCFAs, such as
acetate, bile acid derivatives, and hydrogen species, all of
which can reach the circulation (Nicholson et al., 2012). These
products could influence systemic insulin sensitivity, inflamma-
tion, and energy metabolism either by signaling through
G-protein-coupled receptors (GPCRs), nuclear hormone recep-
tors, or posttranslational modification of host proteins (for
example, lysine acetylation) (Ba¨ckhed et al., 2004, 2007; Nich-678 Cell 152, February 14, 2013 ª2013 Elsevier Inc.olson et al., 2012; Simon et al., 2012).
For example, bile acids can signal
through G-protein-coupled bile acid
receptor (TGR-5) or the farnesoid X
receptor (FXR). It should be kept inmind that these metabolites could also influence CNS satiety
pathways.
The role of bile acids in the crosstalk between hostmetabolism
and the microbiota is particularly intriguing. The microbiota has
a profound influence on circulating bile acid profiles, and bile
acids help to shape the GI microbiota (Nicholson et al., 2012).
Interestingly, gastric bypass surgery has a significant impact
on specific bile acid species, and it is possible that some of
the beneficial effects of bariatric surgery are related to bile acid
profile changes (Patti et al., 2009).
Whether dysbiosis can cause decreased insulin sensitivity
independent of increased adiposity remains an open question.
One study using fecal transplants from lean to obese individuals
improved insulin resistance without altering body weight, fully
consistent with this possibility (Vrieze et al., 2012). Similarly, anti-
biotic treatment of mice ameliorates insulin resistance even
when compared to body-weight-matched controls (Membrez
et al., 2008). However, further studies to establish this concept
will need to more clearly document dysbiosis-induced insulin
resistance independent of increased adiposity. Such studies
should include direct assessment of tissue insulin signaling (liver,
muscle, and fat) and quantitative measurements of in vivo insulin
sensitivity (for example, glucose-clamp studies).
Another outstanding question is whether the effects of dysbio-
sis are due to the outgrowth of particular bacterial species or to
overall functional changes within the collective microbiome. In
support of the latter, the human microbiota shows a high level
of variability in species composition across individuals; however,
metagenomic studies suggest that genes within the microbiome
that pertain to particular functions can be relatively conserved
(Turnbaugh et al., 2009). Similarly, though a core group of
species associated with dysbiosis has not been reproducibly
identified in obese humans, metagenomic studies have indi-
cated that the overall proportion of genes representative of
specific functions, such as increased microbial carbohydrate
metabolism, are associated with obesity (Greenblum et al.,
2012; Turnbaugh et al., 2009). Conclusive determination of mi-
crobiota compositions and metagenomic features associated
with human obesity will require further in-depth study with larger
sample sizes, an objective facilitated by the establishment of the
Human Microbiome Project. The presence of specific species
may bemost relevant tomicrobiota-induced inflammation.While
the majority of intestinal bacteria are restricted to the lumen,
adherence to host cells or invasion beyond the intestine are
important features of select species that promote inflammatory
responses (Hooper et al., 2012). In HFD-fed mice, the profile of
16 s rRNA gene PCR products amplified from blood DNA was
comparatively limited in its diversity compared to DNA from
the cecum, suggesting that only a limited number of species
are capable of reaching the circulation (Amar et al., 2011a). Simi-
larly, sequencing of bacterial DNA from the blood of prediabetic
individuals showed that >85% came from the Proteobacteria
phylum (Amar et al., 2011b). Therefore, in the context of driving
systemic inflammation and insulin resistance, specific species
may well be dominant.
Translation to Man
In general, the data obtained frommouse studies have indicated
that the intestinal microbiota plays an important role in themodu-
lation of obesity and insulin sensitivity (Blumberg and Powrie,
2012; Kau et al., 2011; Nicholson et al., 2012). The effect of the
microbiota in increasing adiposity may be due to the fact that
obesity or HFD, or both, produce a dysbiosis associated with
increased food energy harvest and altered energy metabolism.
Independent of obesity, insulin sensitivity could be adversely ef-
fected by enhancedGI permeability, allowing bacterial products,
such as LPS or bacteria themselves to enter the circulation,
producing proinflammatory effects in insulin target tissues (Bur-
celin et al., 2012). Other mechanisms could also exist, as the mi-
crobiota produce bioactive metabolic products (e.g., bile acids
and SCFAs) and reactive chemical species, such as H2S, which
may alter insulin sensitivity (Nicholson et al., 2012).
It remains to be established how well these processes or
mechanisms observed in mice can be extrapolated to humans.
Unlike mice, which are genetically homogeneous and eat the
same artificially prepared diets, humans consume a range of
diets and are genetically heterogeneous. As a result of this, there
is substantial interindividual variation of microbiota composition
in man, which has made it difficult to identify a core group of
bacterial species that reproducibly define dysbiosis in obese
subjects (Eckburg et al., 2005; Turnbaugh et al., 2009; Wu
et al., 2011b). Despite these marked differences between mice
and humans, some promising clinical investigative studies
have emerged. For example, the blood levels of bacterial DNA
are elevated in prediabetic patients and can be predictive of dia-
betes development in subsequent years, raising the possibility
that blood bacterial DNA may be a biomarker for disease
progression (Amar et al., 2011b). Furthermore, a recent clinical
trial showed improved insulin sensitivity in obese individuals
receiving fecal transplants from lean subjects, even though
body weight was unaffected (Vrieze et al., 2012). Such studies
offer hope that therapeutic ways to modify the GI microbiota
may ultimately emerge.An important issue that could affect any future therapeutic
attempts is that, in humans, the intestinal microbiota tends to
remain fairly stable within an individual over time, suggesting
that, once established in early life, the host adapts to the resident
microbiota in a way that favors the maintenance of the same, or
similar, species composition (Gordon et al., 2012; Nicholson
et al., 2012; Turnbaugh et al., 2009). Microbial ecology and
host immune pathways are likely to predominate in these adap-
tive mechanisms (Hooper et al., 2012; Lemon et al., 2012). For
example, the induction of adaptive immune responses (e.g.,
IgA antibody production) and the secretion of antimicrobial
peptides (e.g., defensins) from GI epithelial cells, Paneth cells,
and innate immune cells could create an environment permissive
for only a select microbiota composition (Hooper et al., 2012).
Supporting this hypothesis, dysbiosis can be induced in mice
by genetic manipulation of immune components (Elinav et al.,
2011; Vijay-Kumar et al., 2010). This might explain why thera-
peutic attempts to change microbiota composition with long-
term probiotic therapy have shown little success (McNulty
et al., 2011). This could also predict that antibiotics may not
prove to be a useful treatment because without changing the
host’s adaptive mechanisms, eventually a similar intestinal mi-
crobiota will grow back. Thus, therapeutic manipulations of
this sort might have to be long term. Furthermore, without
knowing the core species associated with obesity or their antibi-
otic susceptibility, a targeted antibiotic regimen cannot be de-
signed. These are important questions and will need resolution
before the knowledge of the intestinal microbiota and metabolic
disease can be harnessed for therapeutic purposes.
Treatment of Insulin Resistance: Translational
Perspective
Given that obesity is the most common cause of insulin resis-
tance in man and because the obesity epidemic underlies the
increasing prevalence of T2DM, it is obvious that the most effec-
tive form of therapy would be to prevent or treat the underlying
obesity. This has been an elusive therapeutic goal, but new
anti-obesity drugs have recently received FDA approval, indi-
cating progress in this area.
TZDs are PPARg ligands that cause insulin sensitization by
stimulating downstream PPARg transcriptional programs.
They were first introduced into the market in 1997, and two
agents, pioglitazone and rosiglitazone, are still available,
although their use has been curtailed in recent years due to
side effects and potential toxicities. Although it is well known
that these drugs are PPARg ligands, despite many years of
study, their exact mechanisms of action remain unknown
(Tontonoz and Spiegelman, 2008). These drugs have direct
effects in adipocytes, liver, macrophages, skeletal muscle,
Treg cells, and the CNS, and all of these tissue-specific effects
can contribute to overall systemic insulin sensitization
(Tontonoz and Spiegelman, 2008). Although it is recognized
that the improvement in insulin action is due to transcription
of PPARg target genes, the specific target genes responsible
for insulin sensitization and how they work remain unclear
despite many years of study. We know that TZDs can induce
genes involved in insulin action in adipocytes, hepatocytes,
and muscle. They also exert robust anti-inflammatory effectsCell 152, February 14, 2013 ª2013 Elsevier Inc. 679
in immune cells, promote the M2 polarization state of macro-
phages, and enhance Treg cell differentiation and function
(Tontonoz and Spiegelman, 2008). However, a unified mecha-
nism for how these drugs actually cause insulin sensitization
in man has not yet emerged. It is possible that all of these
different tissue-specific effects are additive in vivo and together
account for the insulin-sensitizing effects of this category of
drugs. One thing that is clear is that PPARg itself does not
cause insulin sensitization and that this effect is due to induc-
tion of its target genes. Indeed, Choi et al. have shown that
phosphorylation of PPARg at serine 273 is sufficient to activate
a set of insulin-sensitizing genes in adipocytes (Choi et al.,
2010), and agents that promote this phosphorylation state in
the absence of PPARg agonism can cause insulin sensitization
(Choi et al., 2011). More in-depth study of the set of PPARg
target genes that are responsible for the insulin-sensitizing
effects is warranted, as it is possible that one or more of these
genes could prove to be a more precise and direct target for
future drug discovery.
Having said this, it is probable that PPARg-independent
mechanismswill need to be exploited in order to generate a class
of more effective insulin sensitizers. This is based on observa-
tions that are often overlooked. Although TZDs are potent insulin
sensitizers, in the clinical setting, they only partially correct
insulin resistance. Indeed, if one compares insulin resistant
obese or T2DM patients to normals, then TZD therapy only
corrects insulin resistance 20%–50% toward normal. This
means that TZD-treated patients are still insulin resistant, just
less so. And this is not often appreciated in the clinical setting.
This also shows that a relatively modest effect to improve insulin
sensitivity has a rather robust effect to lower glucose levels in
T2DM subjects. The upside of this observation is that an even
greater degree of glycemic improvement would occur if a treat-
ment could more completely normalize insulin resistance.
Metformin is the most commonly used antidiabetic drug and is
quite effective at reducing levels of HbA1c (glycated hemo-
globin), a measurement that reflects long-term blood glucose
levels (Viollet et al., 2012). Although claims are made that Metfor-
min produces insulin sensitization, the available data indicate
that this is not likely to be the case. Though the mechanism of
action of Metformin is still not fully known, this drug lowers
glucose levels primarily by inhibiting hepatic glucose production.
Because these effects are exerted in a cell-autonomous manner
in hepatocytes and are independent of insulin, this is not insulin
sensitization in the true sense of the word (Viollet et al., 2012).
Therefore, although Metformin is an extremely important and
efficacious antidiabetic agent, it should not properly be classified
as an insulin sensitizer.
A number of additional targets have been pursued to develop
treatments that reduce hepatic glucose production in T2DM. As
this is themainmechanismof action ofMetformin, this is aworth-
while and validated goal. One caveat should be kept in mind in
translating the glucose-lowering efficacy from rodents to man.
Rodents have much higher rates of basal glucose turnover,
and their circulating glucose levels are much more dependent
on hepatic glucose production than in man. In general, hepatic
glucose production is 5- to 10-fold greater on a mg/kg basis in
mice compared to man so that treatments that inhibit excessive680 Cell 152, February 14, 2013 ª2013 Elsevier Inc.hepatic glucose production are more potent in normalizing
glucose levels in rodents than in humans.
Anti-Inflammatory Therapy and Insulin Sensitization
Anti-inflammatory treatments have obvious potential for insulin-
sensitizing therapies. However, attempts at this have not been
overly successful. For example, TNF-a blocking agents have
marked effects to improve insulin sensitivity and lower blood
glucose levels in rodents, but have been either ineffective or
only modestly efficacious in humans (Bernstein et al., 2006;
Dominguez et al., 2005). The reasons for this are unclear. One
potential issue is that TNF-a exerts its effects in a paracrine
fashion and interstitial adipose tissue levels are much higher
than circulating TNF-a concentrations (Hotamisligil et al.,
1995), raising the possibility that the TNF-a blocking agents
have not sufficiently neutralized the relatively high concentra-
tions of TNF-a at its tissue site of action. Nevertheless, one
recent trial of anti-TNF-a treatment in obese individuals showed
a modest reduction in blood glucose levels (Stanley et al., 2011)
and treatment of rheumatoid arthritis patients with TNF-a inhibi-
tors led to a decreased rate of progression to T2DM (Solomon
et al., 2011). Therefore, therapeutic TNF-a blockade in T2DM
could still be a potential goal. IL-1b inhibitors have also been
used in the treatment of T2DM, again with only moderate
success (Larsen et al., 2007; van Asseldonk et al., 2011).
However, whether IL-1b actually plays an important role in the
etiology of the tissue inflammation that leads to insulin resistance
has not been established. On the other hand, inflammation in
pancreatic islets generates IL-1b, which has detrimental effects
on b cell function. Interestingly, the clinical studies with IL-1b
inhibitors indicate that the major effects to improve glycaemia
are related to improved insulin secretion rather than improved
insulin sensitivity (van Asseldonk et al., 2011).
As mentioned above, TZDs exert anti-inflammatory effects,
but in the in vivo state in man, it is hard to tease out to what
degree this aspect of TZD action contributes to the overall insulin
sensitization induced by these drugs. The salicylate prodrug Sal-
salate has showed promising results in this arena, and treatment
of T2DM has demonstrated significant improvement in insulin
sensitivity, as measured by glucose clamps studies, along with
meaningful reductions in HbA1C levels (Goldfine et al., 2010).
The HbA1C reductions are not as robust as typically seen with
other classes of antidiabetic therapy, but perhaps more targeted
and improved anti-inflammatory approaches might be more effi-
cacious.
From a clinical perspective, any anti-inflammatory therapy
must be closely scrutinized for unwanted immune suppression,
which might lead to deleterious side effects. This would suggest
that an anti-inflammatory approach targeted to those elements
of the inflammation pathwaymost directly related to insulin resis-
tance would be preferred. Indeed, until a specific anti-inflamma-
tory agent shows robust efficacy in humans, the role of tissue
inflammation in causing insulin resistance in obese and T2DM
subjects remains incompletely established.
Given that pharmacologic therapy based on targets relevant
to inflammation-induced insulin resistance is still in its early
stages, it is difficult to predict how this field will evolve. An
interesting point often discussed in this context is whether
specific therapies, or targets, might be most effective in
particular subgroups of T2DM insulin-resistant patients. This
type of clinical approach to personalized medicine is increas-
ingly common in cancer therapeutics but has not yet reached
the level of evidence-based treatment in T2DM. Perhaps anti-
inflammatory treatment would be particularly efficacious in
subgroups of patients with T2DM with large components of
inflammation-induced insulin resistance. This would require
specific biomarkers to identify subphenotypes within the spec-
trum of T2DM that predict responsiveness to particular thera-
peutic modalities.
Conclusions
It is clear that additional approaches are needed to develop new
insulin-sensitizing compounds and that new treatment opportu-
nities will be of great help in our ability to mitigate the current
T2DM epidemic. The results of gastric bypass surgeries offer
a hopeful outlook on this. It is now well recognized that bariatric
surgery can lead to rapid improvements in insulin resistance and
decreases in glycaemia in T2DM patients well in advance of the
onset of significant weight reduction. So far, the mechanisms for
this early amelioration of insulin resistance and hyperglycemia
following bariatric surgery remain unknown. Whether it is due
to postsurgical secretion of a new incretin or some other factor
with beneficial effects or is due to reduced secretion of a diabe-
togenic factor is unknown. Possibly, the rearrangement of the
gastrointestinal tract has major effects on the microbiota (Li
et al., 2011; Zhang et al., 2009) or the pathophysiology of
systemic inflammation. Regardless of the mechanism, the
remarkable acute postbariatric surgery results indicate that it is
possible to develop insulin-sensitizing therapies with much
greater glucose-lowering efficacy then current treatments allow.
Insulin resistance is obviously a key pathogenic feature of
T2DM with a complex, multifactorial etiology. Newer and more
efficacious insulin-sensitizing therapies are badly needed, but
despite the importance of this issue and intense efforts over
the past decades, no new insulin sensitizers have been intro-
duced into the clinical arena since the advent of TZDs in 1997.
This is a rather remarkable fact and underscores the difficulties
involved. As there are multiple interacting mechanisms of insulin
resistance, many approaches to developing insulin-sensitizing
therapeutics are possible, and likely several will be necessary.
Yet, because of the recent progress in defining the interwoven
influences of inflammation, lipid metabolism, and themicrobiota,
multiple new targets are emerging that offer the possibility,
through a concerted and integrated effort, to confront and
ameliorate the diabetes epidemic.
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